Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
85 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Primary Sclerosing Cholangitis - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Primary Sclerosing Cholangitis - Pipeline Review, H1 2016', provides an overview of the Primary Sclerosing Cholangitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis - The report reviews pipeline therapeutics for Primary Sclerosing Cholangitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Primary Sclerosing Cholangitis therapeutics and enlists all their major and minor projects - The report assesses Primary Sclerosing Cholangitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Primary Sclerosing Cholangitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Primary Sclerosing Cholangitis Overview 7 Therapeutics Development 8 Pipeline Products for Primary Sclerosing Cholangitis - Overview 8 Primary Sclerosing Cholangitis - Therapeutics under Development by Companies 9 Primary Sclerosing Cholangitis - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Unknown Stage Products 12 Primary Sclerosing Cholangitis - Products under Development by Companies 13 Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development 14 Biotie Therapies Corp. 14 ChemoCentryx, Inc. 15 Dr. Falk Pharma GmbH 16 Gilead Sciences, Inc. 17 Intercept Pharmaceuticals, Inc. 18 NGM Biopharmaceuticals, Inc. 19 Sancilio & Company, Inc. 20 Shire Plc 21 Takeda Pharmaceutical Company Limited 22 TGV-Laboratories 23 Tobira Therapeutics, Inc. 24 Primary Sclerosing Cholangitis - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 bertilimumab - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 BTT-1023 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 CCX-507 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 cenicriviroc mesylate - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Cyndacel-M - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Hep-114 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 NGM-282 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 norursodeoxycholic acid - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 obeticholic acid - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 SC-404 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 SHP-625 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 simtuzumab - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 vedolizumab - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Primary Sclerosing Cholangitis - Recent Pipeline Updates 56 Primary Sclerosing Cholangitis - Dormant Projects 76 Primary Sclerosing Cholangitis - Product Development Milestones 77 Featured News & Press Releases 77 Jan 07, 2016: Tobira Therapeutics Announces Initiation of Program to Evaluate Cenicriviroc for the Treatment of Primary Sclerosing Cholangitis 77 Nov 09, 2015: NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015 77 Nov 03, 2015: Intercept Announces Data to be Presented at the 2015 AASLD Annual Meeting 78 Mar 31, 2015: Biotie announces start of patient enrolment into Phase 2a clinical study with BTT1023 in primary sclerosing cholangitis 81 Feb 17, 2015: BTT1023 receives positive opinion for Orphan Drug Designation from COMP 81 Jul 24, 2014: Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding 81 Nov 18, 2013: Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases 82 Sep 26, 2013: Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases 83 Appendix 84 Methodology 84 Coverage 84 Secondary Research 84 Primary Research 84 Expert Panel Validation 84 Contact Us 84 Disclaimer 85
List of Tables
Number of Products under Development for Primary Sclerosing Cholangitis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Comparative Analysis by Unknown Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Primary Sclerosing Cholangitis - Pipeline by Biotie Therapies Corp., H1 2016 14 Primary Sclerosing Cholangitis - Pipeline by ChemoCentryx, Inc., H1 2016 15 Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, H1 2016 16 Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences, Inc., H1 2016 17 Primary Sclerosing Cholangitis - Pipeline by Intercept Pharmaceuticals, Inc., H1 2016 18 Primary Sclerosing Cholangitis - Pipeline by NGM Biopharmaceuticals, Inc., H1 2016 19 Primary Sclerosing Cholangitis - Pipeline by Sancilio & Company, Inc., H1 2016 20 Primary Sclerosing Cholangitis - Pipeline by Shire Plc, H1 2016 21 Primary Sclerosing Cholangitis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 22 Primary Sclerosing Cholangitis - Pipeline by TGV-Laboratories, H1 2016 23 Primary Sclerosing Cholangitis - Pipeline by Tobira Therapeutics, Inc., H1 2016 24 Assessment by Monotherapy Products, H1 2016 25 Number of Products by Stage and Target, H1 2016 27 Number of Products by Stage and Mechanism of Action, H1 2016 29 Number of Products by Stage and Route of Administration, H1 2016 31 Number of Products by Stage and Molecule Type, H1 2016 33 Primary Sclerosing Cholangitis Therapeutics - Recent Pipeline Updates, H1 2016 56 Primary Sclerosing Cholangitis - Dormant Projects, H1 2016 76
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.